Business Wire

OCP-TAP approves Adtran’s OSA 5400 TimeCard™ for precise, resilient data center timing

28.9.2023 15:00:00 EEST | Business Wire | Press release

Share

Adtran today announced that the Open Compute Project (OCP) Time Appliance Project (TAP) has approved its OSA 5400 TimeCard™ for data center timing and synchronization. The pluggable device injects Adtran’s Oscilloquartz timing technology into any white box server, solving key challenges in the transition to virtualized environments. The OCP-TAP’s endorsement means data center operators leveraging the OSA 5400 TimeCard to synchronize COTS hardware can be assured of precise, reliable and robust timing as they move to more cost-efficient and scalable network architectures.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230928894327/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The OSA 5400 TimeCard™ represents a simple route to accurate, reliable and robust data center timing. (Photo: Business Wire)

“We’re pleased to be able to announce that Adtran’s OSA 5400 TimeCard now supports the OCP-TAP driver. It’s an important milestone in our collective quest to advance robust and accurate timing solutions for distributed system use cases. By meeting our framework’s specifications, Adtran is helping us drive standardization and interoperability, accelerating the industry’s shift to open, standardized hardware,” said Ahmad Byagowi, TAP project leader at OCP-TAP. “This pluggable solution represents a simple route to accurate, reliable and robust data center timing. We believe that solutions like the OSA 5400 TimeCard will play a pivotal role in advancing the next generation of scalable and resilient infrastructure.”

Enabling data center operators to efficiently host the most demanding time-sensitive applications, Adtran’s OSA 5400 TimeCard plugs into any free PCIe slot to turn a standard COTS server into a precise PTP grandmaster clock or NTP server. With multiple oscillator options, the solution ensures accurate timing even during extended periods of GNSS disturbances. In combination with Adtran’s Ensemble Sync Director, the OSA 5400 TimeCard provides operational teams with a comprehensive, unified view of their entire timing infrastructure. This enables them to easily manage all elements of their timing network, enhancing control and reliability. What’s more, the OSA 5400 TimeCard has been developed to align fully with the IEEE P3335 standardization, ensuring adaptability and underscoring Adtran’s commitment to industry advancement in a cohesive digital ecosystem.

“We’re proud that our OSA 5400 TimeCard has been validated by OCP-TAP. This card brings our 74 years of expertise in timing and synchronization to standard servers, going beyond the TAP specifications to provide a scalable, fully featured timing solution in a compact half-size PCIe card. It offers a major boost for data center operators looking to embrace open, disaggregated hardware, especially where timing is vital and space is limited. Our OSA 5400 TimeCard ensures seamless, efficient operation of mission-critical and time-sensitive applications,” commented Igal Pinhasov, VP of PLM at Oscilloquartz, Adtran. “As the industry progresses towards agile, cost-effective data center environments, our pluggable timing technology will play a defining role in shaping future architectures.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and Twitter.

Published by
ADTRAN Holdings, Inc.
www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media
Gareth Spence
+44 1904 699 358
public-relations@adva.com

For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye